UBS Maintains Neutral on RXO, Raises Price Target to $30.25
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $23 to $30.25.
UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $23 to $30.25.